Skip to main content

Table 1 Baseline characteristics.

From: Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register

Characteristic Etanercept Infliximab Adalimumab Anakinra Biologics total Control
N 397 255 121 45 818 265
Age 53.2 (12.5) 54.0 (12.3) 53.8 (12.4) 56.2 (11.2) 53.7 (12.3) 57.4 (10.3)
Female (%) 79.1 71.0 85.1 73.3 76.6 83.8
Disease duration (years), median (IQR) 10 (6–18) 9 (5–14) 12 (7–19) 13 (7–21) 10 (6–17) 9 (5–17)
Rheumatoid factor positive (%) 82.1 83.5 84.3 77.8 82.2 77.7
Swollen joint count 10.2 (6.2) 11.3 (6.4) 9.6. (6.4) 10.9 (6.6) 10.5 (6.3) 8.2 (5.3)
Tender joint count 13.0 (7.3) 13.0 (7.4) 12.3 (7.4) 13.6 (7.3) 12.9 (7.3) 10.5 (6.9)
ESR (mm/h), median (IQR) 33 (20–54) 32 (18–54) 30 (17–44) 36 (22–51) 32 (18–53) 23 (14–37)
CRP (mg/l), median (IQR) 20 (7–42) 18 (7–48) 18 (7–32) 21 (6–36) 18 (7–42) 12 (4–27)
DAS28 6.1 (1.1) 6.2 (1.2) 5.9 (1.2) 6.3 (1.0) 6.1 (1.1) 5.5 (1.1)
FFbH 53.4 (22.9) 52.8 (20.9) 53.2 (25.1) 52.7 (23.3) 53.1 (22.8) 61.4 (22.4)
Number of previous DMARDs 3.9 (1.3) 3.9 (1.4) 4.4 (1.3) 4.3 (1.6) 4.0 (1.4) 2.8 (0.9)
Current treatment DMARD (%)       
   MTX alone 33.0 67.5 43.0 60.0 46.7 1.5
   Other single DMARD 11.9 14.5 8.3 8.8 12.0 29.8
   Combination of two DMARDs 5.3 8.6 5.8 4.4 6.4 57.3
   Combinations of three DMARDs 1.3 1.6 1.6 0.0 1.3 11.3
   No DMARD 48.6 7.8 41.3 26.7 33.6 0
Biologic dose/week (mg)a 49.7 (4.1) 4.0 (1.9) 21.5 (7.0) 700 (0) - -
Comorbidity (%) 72.6 68.5 64.5 71.1 70.0 72.8
Osteoporosis (%) 30.2 27.9 22.3 35.6 28.6 18.5
  1. Values are means and standard deviations if not otherwise specified. CRP, C-reactive protein; DAS28, disease activity score based on 28 joint counts; DMARD, disease modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; FFbH, Funktionsfragebogen Hannover (Hannover Functional Status Questionnaire); IQR, inter quartile range. aEtanercept, adalimumab and anakinra, mean dosage/week; infliximab, mean dosage/8 weeks and kg body weight, time intervals between the applications were taken into account.